	US 11,807,661 B2
	Antibody fusion protein and related compositions for targeting cancer
Rachael Sirianni, San Francisco, CA (US); Rebecca Cook, Scottsdale, AZ (US); Tsafrir Mor, Tempe, AZ (US); and Joseph Blattman, Scottsdale, AZ (US)
Assigned to Dignity Health, San Francisco, CA (US); and Arizona Board of Regents on Behalf of Arizona State University, Tempe, AZ (US)
Filed by Dignity Health, Phoenix, AZ (US); and Arizona Board of Regents on Behalf of Arizona State University, Scottsdale, AZ (US)
Filed on Jul. 14, 2020, as Appl. No. 16/929,001.
Application 16/929,001 is a division of application No. 15/999,241, granted, now 10,745,478, previously published as PCT/US2017/018472, filed on Feb. 17, 2017.
Claims priority of provisional application 62/297,502, filed on Feb. 19, 2016.
Prior Publication US 2020/0339679 A1, Oct. 29, 2020
Int. Cl. A61K 35/00 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); C12N 15/82 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); C12N 15/86 (2006.01); C12N 15/74 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 9/0019 (2013.01); A61K 47/6817 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C12N 15/743 (2013.01); C12N 15/8258 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/33 (2013.01); C07K 2319/55 (2013.01)]

16 Claims

1. A method of treating cancer in a subject, comprising:

providing a composition comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain comprises a chlorotoxin peptide and/or a chlorotoxin-like peptide and is capable of binding to a cancer cell;

wherein the composition includes a sequence comprising SEQ ID NO: 9. SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12; and

treating the cancer by administering a therapeutically effective dosage of the composition to the subject.